| Identification | Back Directory | [Name]
4-hydroxy-N'-(2-naphthylmethylene)benzohydrazide | [CAS]
303760-60-3 | [Synonyms]
SLU-PP
SLU-PP-332
4-hydroxy-N'-(2-naphthylmethylene)benzohydrazide
4-hydroxy-N'-[(E)-naphthalen-2-ylmethylidene]benzohydrazide
Benzoic acid, 4-hydroxy-, 2-(2-naphthalenylmethylene)hydrazide | [EINECS(EC#)]
218-362-5 | [Molecular Formula]
C18H14N2O2 | [MDL Number]
MFCD00595076 | [MOL File]
303760-60-3.mol | [Molecular Weight]
290.32 |
| Chemical Properties | Back Directory | [density ]
1.20±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 2mg/mL, clear (Warmed) | [form ]
Solid | [pka]
8.44±0.15(Predicted) | [color ]
White to off-white | [InChI]
InChI=1S/C18H14N2O2/c21-17-9-7-15(8-10-17)18(22)20-19-12-13-5-6-14-3-1-2-4-16(14)11-13/h1-12,21H,(H,20,22) | [InChIKey]
RNZIMBFHRXYRLL-UHFFFAOYSA-N | [SMILES]
C(NN=CC1=CC=C2C(=C1)C=CC=C2)(=O)C1=CC=C(O)C=C1 |
| Hazard Information | Back Directory | [Description]
SLU-PP-332 is a synthetic estrogen receptor-related orphan receptor (ERR) agonist which activates an amplified aerobic exercise mode. SLU-PP-332 does not affect food intake, appetite, or exercise initiation. This agent improves a natural metabolic pathway that characteristically reacts to exercise, resulting in amplified energy expenditure and extra body fat metabolism. SLU-PP-332 enhances mitochondrial function and cellular respiration in skeletal muscle cell lines, increases the expression of an ERR target gene [pyruvate dehydrogenase kinase 4 (Pdk4)], and enhances mitochondrial respiration in C2C12 myocytes.
| [Uses]
SLU-PP-332 is a pan-Estrogen Receptor/ERR agonist with EC50 values of 98, 230 and 430 nM for ERRα, ERRβ and ERRγ, respectively. SLUPP-332 enhances mitochondrial function and cellular respiration in skeletal muscle cell lines. SLU-PP-332 has the potential to study metabolic diseases as well as improve muscle function[1]. | [benefits]
SLU-PP-332 improves a natural metabolic route, which typically happens in response to exercise; it amplifies energy expenditure and results in faster body fat metabolism. SLU-PP-332 enhances mitochondrial function and cellular respiration in skeletal muscle cell lines, increases the expression of an ERR target gene [pyruvate dehydrogenase kinase 4 (Pdk4)], and enhances mitochondrial respiration in C2C12 myocytes. The drug also increases oxidative fibres in skeletal muscle and improved exercise endurance in C57BL/6J mice. This drug works on a group of proteins throughout the body organs called ERRs that activate some of the most significant metabolic pathways in the body, including the cardiac cells and the brain tissue. The drug can potentially transform the future of fitness and can facilitate weight loss by stimulating the body’s muscles during exercise. The mechanism of action of SLU-PP-332 is to activate ERRs, leading to increased energy expenditure, fatty acid oxidation, and decreased fat mass accumulation.
| [Mechanism of action]
SLU-PP-332 enhances mitochondrial function and cellular respiration in skeletal muscle cell lines, increases the expression of an estrogen receptor-related orphan receptor target gene, and enhances mitochondrial respiration in C2C12 myocytes. | [in vivo]
SLU-PP-332 (50 mg/kg, i.p., a single dose for 28 or 12 days) increases mitochondrial function and cellular respiration in a skeletal muscle cell line and induces an ERRα-specific acute aerobic exercise genetic program in mice[1].
SLU-PP-332 (50 mg/kg, i.p., twice per day for 28 days or 12 days) induces fatty acid metabolism, reduces fat mass and improves glucose metabolism in diet-induced obesity mouse models[3].
| Animal Model: | 8-10 male C57BL/6J mice[1] | | Dosage: | 50 mg/kg | | Administration: | i.p., a single dose for 28 or 12 days | | Result: | Displayed a more oxidative muscle phenotype, increased the complex I (NDUFB8) and complex V (ATP5A) protein expression in the gastrocnemius muscle and cytochrome C, mitochondria content and oxidative type IIa muscle fibers lavels in mice. |
| Animal Model: | High fat diet-induced obesity mouse model[3] | | Dosage: | 50 mg/kg | | Administration: | i.p., twice per day for 28 days or 12 days | | Result: | Did not alter brown adipose tissue mass, daily food intake and glucose metabolism, increased fatty acid oxidation (FAO) in normal in C57Bl/6 mice, but induced a progressive weight loss and decreased adipocytes size in high fat diet-induced obesity mouse models. |
| [IC 50]
ERRα: 98 nM (EC50); ERRβ: 230 nM (EC50); ERRγ: 430 nM (EC50) | [References]
[1] Nasri, Hamid. “New hopes on ‘SLU-PP-332’ as an effective agent for weight loss with indirect kidney protection efficacy; a nephrology point of view.” Journal of Renal Endocrinology 26 7 (2024).
|
|
|